Proteomic Biomarkers in Pancreatic Cyst Fluids

胰腺囊肿液中的蛋白质组生物标志物

基本信息

  • 批准号:
    7125950
  • 负责人:
  • 金额:
    $ 8.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-09-30 至 2008-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Pancreatic cancer is the fourth leading cause of cancer death in the United States. The majority of cases are diagnosed late with poor prognosis. Only approximately 20% of the minority of patients that undergo surgical resection with curative intent will survive for five years. There are several different types of unique pancreatic cystic neoplasms and some have malignant potential. They are initially benign lesions, but a mucin-producing subgroup can progress through a series of malignant transformations, leading to the development of adenocarcinoma. Surgical resection is the current standard of care for mucinous cystic neoplasms, but a growing number of pancreatic cysts are being detected by improved diagnostic radiology. In many cases, the etiology of a given cyst and its potential for malignancy remains indeterminate, making it extremely difficult to make recommendations for, or against, a major abdominal surgical intervention (i.e., pancreatic resection). Endoscopic ultrasound with fine needle aspiration is used to obtain cyst fluid to analyze for biomarkers and cytology, but existing biomarkers have limited sensitivity, specificity, predictive values, and accuracy. To our knowledge, proteomic analysis of pancreatic cyst fluid has not been described. We propose to collect cyst fluids from approximately 20 patients to perform a proteomics feasibility study. Our hypothesis is that the protein composition of each individual cyst type contains useful and unique signatures that can be identified by detailed mapping of its proteins, and that these unique signatures will eventually help clinicians to better manage patients with cystic lesions of the pancreas. Specific Aim 1: To characterize the medium molecular weight proteins of the fluids of various cyst types by 2D gel proteomics complemented by a global digestion multidimensional LC/MS/MS proteomics approach. Specific Aim 2: To elicudate the small peptide proteome of the fluids of various cyst types using both MALDI-TOF mass spectrometry and LC/MS/MS mass spectrometry. It is anticipated that this project will provide detailed proteomic definition of the fluids of various types of cystic lesions of the pancreas from which new and more effective biomarkers of malignancy can be selected and validated in future.
描述(由申请人提供):胰腺癌是美国癌症死亡的第四大原因。大多数病例诊断晚,预后差。只有大约20%的少数患者接受手术切除治疗的目的将生存五年。有几种不同类型的独特的胰腺囊性肿瘤,有些具有恶性潜力。它们最初是良性病变,但产生粘蛋白的亚群可以通过一系列恶性转化而进展,导致腺癌的发展。手术切除是目前治疗粘液性囊性肿瘤的标准,但越来越多的胰腺囊肿被诊断放射学的改进所发现。在许多情况下,给定囊肿的病因及其恶性肿瘤的可能性仍然不确定,使得极难推荐或反对重大腹部手术干预(即,胰腺切除术)。使用细针抽吸的内窥镜超声来获得囊液以分析生物标志物和细胞学,但现有的生物标志物具有有限的灵敏度、特异性、预测值和准确性。 据我们所知,胰腺囊肿液的蛋白质组学分析尚未被描述。我们建议收集约20例患者的囊肿液进行蛋白质组学可行性研究。我们的假设是,每种囊肿类型的蛋白质组成都包含有用和独特的特征,可以通过对其蛋白质的详细映射来识别,并且这些独特的特征最终将帮助临床医生更好地管理胰腺囊性病变患者。具体目标1:通过二维凝胶蛋白质组学结合整体消化多维LC/MS/MS蛋白质组学方法表征各种囊肿类型液体的中分子量蛋白质。具体目标二:采用MALDI-TOF质谱和LC/MS/MS质谱技术分析不同类型包囊液中的小肽蛋白质组。预计该项目将提供各种类型胰腺囊性病变液体的详细蛋白质组学定义,从中可以选择新的和更有效的恶性肿瘤生物标志物并在未来进行验证。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Proteomic analyses of pancreatic cyst fluids.
  • DOI:
    10.1097/mpa.0b013e318193a08f
  • 发表时间:
    2009-03
  • 期刊:
  • 影响因子:
    2.9
  • 作者:
    Ke E;Patel BB;Liu T;Li XM;Haluszka O;Hoffman JP;Ehya H;Young NA;Watson JC;Weinberg DS;Nguyen MT;Cohen SJ;Meropol NJ;Litwin S;Tokar JL;Yeung AT
  • 通讯作者:
    Yeung AT
Potential prognostic biomarkers of pancreatic cancer.
  • DOI:
    10.1097/mpa.0b013e3182a6867e
  • 发表时间:
    2014-01
  • 期刊:
  • 影响因子:
    2.9
  • 作者:
    Chen KT;Kim PD;Jones KA;Devarajan K;Patel BB;Hoffman JP;Ehya H;Huang M;Watson JC;Tokar JL;Yeung AT
  • 通讯作者:
    Yeung AT
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANTHONY T YEUNG其他文献

ANTHONY T YEUNG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANTHONY T YEUNG', 18)}}的其他基金

Proteomic Validation of the Min Mouse Model of Colon Cancer
结肠癌小鼠模型的蛋白质组学验证
  • 批准号:
    7215018
  • 财政年份:
    2006
  • 资助金额:
    $ 8.35万
  • 项目类别:
Proteomic Validation of the Min Mouse Model of Colon Cancer
结肠癌小鼠模型的蛋白质组学验证
  • 批准号:
    7289221
  • 财政年份:
    2006
  • 资助金额:
    $ 8.35万
  • 项目类别:
Proteomic Biomarkers in Pancreatic Cyst Fluids
胰腺囊肿液中的蛋白质组生物标志物
  • 批准号:
    7036308
  • 财政年份:
    2005
  • 资助金额:
    $ 8.35万
  • 项目类别:
CORE--BIOCHEMISTRY AND BIOTECHNOLOGY
核心--生物化学与生物技术
  • 批准号:
    6652204
  • 财政年份:
    2002
  • 资助金额:
    $ 8.35万
  • 项目类别:
CORE--BIOCHEMISTRY AND BIOTECHNOLOGY
核心--生物化学与生物技术
  • 批准号:
    6485970
  • 财政年份:
    2001
  • 资助金额:
    $ 8.35万
  • 项目类别:
DNA REPAIR POLYMORPHISMS AND SPORADIC BREAST CANCER
DNA 修复多态性与散发性乳腺癌
  • 批准号:
    6378000
  • 财政年份:
    2000
  • 资助金额:
    $ 8.35万
  • 项目类别:
DNA REPAIR POLYMORPHISMS AND SPORADIC BREAST CANCER
DNA 修复多态性与散发性乳腺癌
  • 批准号:
    6166746
  • 财政年份:
    2000
  • 资助金额:
    $ 8.35万
  • 项目类别:
CORE--FERMENATION
核心--发酵
  • 批准号:
    6396696
  • 财政年份:
    1999
  • 资助金额:
    $ 8.35万
  • 项目类别:
CORE--PROTEIN ANALYSIS AND PEPTIDE SYNTHESIS
核心--蛋白质分析与肽合成
  • 批准号:
    6395514
  • 财政年份:
    1999
  • 资助金额:
    $ 8.35万
  • 项目类别:
CORE--PROTEIN ANALYSIS AND PEPTIDE SYNTHESIS
核心--蛋白质分析与肽合成
  • 批准号:
    6395540
  • 财政年份:
    1999
  • 资助金额:
    $ 8.35万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.35万
  • 项目类别:
    Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 8.35万
  • 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 8.35万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 8.35万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 8.35万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 8.35万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 8.35万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 8.35万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 8.35万
  • 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
  • 批准号:
    10828252
  • 财政年份:
    2023
  • 资助金额:
    $ 8.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了